FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:950-952 August 31, 2006 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Bertagnolli, M. M. PubMed Citation

In late September 2004, the cardiovascular risks identified in a placebo-controlled adenoma-prevention trial that was terminated early precipitated the voluntary withdrawal from the market of the cyclooxygenase-2 (COX-2) inhibitor rofecoxib.¹ Later that year, in another adenoma-prevention trial, the COX-2 inhibitor, celecoxib, was also associated with an increase in the risk of cardiovascular events.² For this reason, on December 17, 2004, the data and safety monitoring boards of two celecoxib trials recommended stopping drug administration in the trials.^2,3 Articles describing the cardiovascular risks seen in the two adenoma prevention trials were published rapidly.^1,4 However, in the absence of evidence about the . . . [Full Text of this Article]

Source Information

From the Cardiovascular Health Research Unit, Departments of Medicine (B.M.P.), Epidemiology (B.M.P., J.D.P.), and Health Services (B.M.P.), University of Washington; and the Division of Public Health Sciences, Fred Hutchinson Cancer Research Center (J.D.P.) — both in Seattle.

Related Letters:

Risks and Benefits of Celecoxib to Prevent Colorectal Adenomas
Andersohn F., Suissa S., Garbe E., Solomon S., Wittes J., Arber N., Bertagnolli M., Hawk E., Levin B., the APC and PreSAP Trial Investigators , Psaty B. M., Potter J. D.
Extract | Full Text | PDF  
N Engl J Med 2006; 355:2371-2373, Nov 30, 2006. Correspondence

This article has been cited by other articles:

• Thomasset, S., Berry, D. P., Cai, H., West, K., Marczylo, T. H., Marsden, D., Brown, K., Dennison, A., Garcea, G., Miller, A., Hemingway, D., Steward, W. P., Gescher, A. J. (2009). Pilot Study of Oral Anthocyanins for Colorectal Cancer Chemoprevention. Cancer Prevention Research 2: 625-633 [Abstract] [Full Text]  
• Dance-Barnes, S. T., Kock, N. D., Moore, J. E., Lin, E. Y., Mosley, L. J., D'Agostino, R. B. Jr, McCoy, T. P., Townsend, A. J., Miller, M. S. (2009). Lung tumor promotion by curcumin. Carcinogenesis 30: 1016-1023 [Abstract] [Full Text]  
• Zell, J. A., Pelot, D., Chen, W.-P., McLaren, C. E., Gerner, E. W., Meyskens, F. L. (2009). Risk of Cardiovascular Events in a Randomized Placebo-Controlled, Double-Blind Trial of Difluoromethylornithine plus Sulindac for the Prevention of Sporadic Colorectal Adenomas. Cancer Prevention Research 2: 209-212 [Abstract] [Full Text]  
• Krueger, K, Lino, L, Dore, R, Radominski, S, Zhang, Y, Kaur, A, Simpson, R, Curtis, S (2008). Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II). Ann Rheum Dis 67: 315-322 [Abstract] [Full Text]  
• Keku, T. O., Amin, A., Galanko, J., Martin, C., Schliebe, B., Sandler, R. S. (2008). Apoptosis in Normal Rectal Mucosa, Baseline Adenoma Characteristics, and Risk of Future Adenomas. Cancer Epidemiol. Biomarkers Prev. 17: 306-310 [Abstract] [Full Text]  
• Sedjo, R. L., Byers, T., Barrera, E. Jr., Cohen, C., Fontham, E. T. H., Newman, L. A., Runowicz, C. D., Thorson, A. G., Thun, M. J., Ward, E., Wender, R. C., Eyre, H. J., for the ACS Cancer Incidence & Mortality Ends Comm, (2007). A Midpoint Assessment of the American Cancer Society Challenge Goal to Decrease Cancer Incidence by 25% Between 1992 and 2015. CA Cancer J Clin 57: 326-340 [Abstract] [Full Text]  
• Bock, J. M., Menon, S. G., Sinclair, L. L., Bedford, N. S., Goswami, P. C., Domann, F. E., Trask, D. K. (2007). Celecoxib Toxicity Is Cell Cycle Phase Specific. Cancer Res. 67: 3801-3808 [Abstract] [Full Text]  
• Armstrong, D. J. (2007). Celecoxib and CVS risk--lessons from the APC and PreSAP studies. Rheumatology (Oxford) 46: 561-562 [Full Text]  
• Rostom, A., Dube, C., Lewin, G., Tsertsvadze, A., Barrowman, N., Code, C., Sampson, M., Moher, D. (2007). Nonsteroidal Anti-inflammatory Drugs and Cyclooxygenase-2 Inhibitors for Primary Prevention of Colorectal Cancer: A Systematic Review Prepared for the U.S. Preventive Services Task Force. ANN INTERN MED 146: 376-389 [Abstract] [Full Text]  
• Hawk, E., Viner, J. L. (2007). The Adenoma Prevention with Celecoxib and Prevention of Colorectal Sporadic Adenomatous Polyps Trials: Stepping Stones to Progress. Cancer Epidemiol. Biomarkers Prev. 16: 185-187 [Full Text]  
• Levine, J. S., Ahnen, D. J. (2006). Adenomatous Polyps of the Colon. NEJM 355: 2551-2557 [Full Text]  
• Jewett, A., Head, C., Cacalano, N.A. (2006). Emerging Mechanisms of Immunosuppression in Oral Cancers. JDR 85: 1061-1073 [Abstract] [Full Text]  
• (2006). Celecoxib Update: Cardiovascular Risk vs. Polyp-Prevention Benefit. Journal Watch Cardiology 2006: 1-1 [Full Text]  
• (2006). Coxibs and Colon Polyps: Efficacy with Prohibitive Risk!. JWatch Gastroenterology 2006: 1-1 [Full Text]  
• (2006). Celecoxib for Prevention of Colorectal Polyps. JWatch General 2006: 1-1 [Full Text]